Cancidas

Cancidas is a brand name of caspofungin, approved by the FDA in the following formulation(s):

CANCIDAS (caspofungin acetate - injectable; iv (infusion))

• 
  Manufacturer: MERCK
  
  Approval date: January 26, 2001
  
  Strength(s): 50MG/VIAL ^[RLD], 70MG/VIAL ^[RLD]

Has a generic version of Cancidas been approved?

No. There is currently no therapeutically equivalent version of Cancidas available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cancidas. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aza cyclohexapeptide compounds
  Patent 5,378,804
  Issued: January 3, 1995
  Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
  Assignee(s): Merck & Co., Inc.
  Aza cyclohexapeptide compounds are disclosed with a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxyornithine component. Such compounds are represented by the formula: ##STR1## The compounds are disclosed as having antifungal, antiprotozoal and anti-Pneumocystis carinii activity.
  
  Patent expiration dates:
  
  
  • March 16, 2013
    
    ✓ 
    Drug substance
  
  
  
  • September 16, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Aza cyclohexapeptide compounds
  Patent 5,514,650
  Issued: May 7, 1996
  Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
  Assignee(s): Merck & Co., Inc.
  Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
  
  Patent expiration dates:
  
  
  • January 26, 2015
    
    ✓ 
    Patent use: CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
    ✓ 
    Drug product
  
  
  
  • July 26, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Aza cyclohexapeptide compounds
  Patent 5,792,746
  Issued: August 11, 1998
  Inventor(s): Balkovec; James M. & Bouffard; Frances Aileen & Black; Regina M.
  Assignee(s): Merck & Co., Inc.
  Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
  
  Patent expiration dates:
  
  
  • March 16, 2013
    
    ✓ 
    Patent use: CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 16, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Antifungal compositions
  Patent 5,952,300
  Issued: September 14, 1999
  Inventor(s): Nerurkar; Maneesh J. & Hunke; William A. & Kaufman; Michael J.
  Assignee(s): Merck & Co., Inc.
  The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
  
  Patent expiration dates:
  
  
  • March 28, 2017
    
    ✓ 
    Drug product
  
  
  
  • September 28, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Antifungal compositions
  Patent 6,136,783
  Issued: October 24, 2000
  Inventor(s): Neururkar; Maneesh J. & Kaufman; Michael J. & Hunke; William A.
  Assignee(s): Merck & Co., Inc.
  The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
  
  Patent expiration dates:
  
  
  • March 28, 2017
    
    ✓ 
    Patent use: CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
  
  
  
  • September 28, 2017
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Cancidas Consumer Information (Wolters Kluwer)
• Cancidas Consumer Information (Cerner Multum)
• Cancidas Advanced Consumer Information (Micromedex)
• Cancidas AHFS DI Monographs (ASHP)
• Caspofungin Consumer Information (Wolters Kluwer)
• Caspofungin Consumer Information (Cerner Multum)
• Caspofungin Intravenous Advanced Consumer Information (Micromedex)
• Caspofungin Acetate AHFS DI Monographs (ASHP)